Harmony Biosciences Holdings (HRMY): One of the Best Stocks to Buy According to AI

We just covered the 10 Best Stocks to Buy Right Now According to AI and Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) ranks 10th on this list.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a commercial-stage pharmaceutical company focused on developing therapies for patients suffering from rare neurological diseases. The flagship commercial product is WAKIX (pitolisant), a first-in-class medication approved by the FDA to treat excessive daytime sleepiness or cataplexy in adult patients with narcolepsy. Pitolisant functions through a novel mechanism of action that increases histamine release in the brain to promote wakefulness. Harmony is actively working to expand its market footprint by seeking regulatory approvals for pediatric narcolepsy and exploring treatments for idiopathic hypersomnia and Prader-Willi syndrome.

The Allstate Corporation (ALL): One of the Best 52-Week High Insurance Stocks to Invest In According to Short Sellers

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) recently posted impressive Q1 2026 financial results, which featured total revenues of $215.4 million, representing a 17% year-over-year growth driven by the sustained adoption of WAKIX. Management reaffirmed its full-year 2026 net revenue guidance of over $1 billion, signaling durable commercial momentum and stable market demand. The business exhibits exceptional operating leverage, converting its top-line growth into strong cash generation that comfortably funds its late-stage clinical pipeline. Investors are particularly optimistic about Harmony’s lifecycle management strategies for pitolisant and its newer pipeline assets.

While we acknowledge the risk and potential of HRMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than HRMY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: Growth Stock Portfolio: 12 Stock Picks by Carl C. Icahn and Chris Rokos Stock Portfolio: Top 10 Stock Picks.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1